Publications by authors named "Roger Dansey"

Claim this Profile
N
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31Annual Meeting of the Society for Immunotherapy of Cancer, 2016.
Prasad S Adusumilli, Edward Cha, Mark Cornfeld, Thomas Davis, Adi Diab, Roger D Dansey

J Immunother Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
Susan M O'Brien, Nicole Lamanna, Thomas J Kipps, Ian Flinn, Andrew D Zelenetz, Roger D Dansey

Blood· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
David Henry, Saroj Vadhan-Raj, Vera Hirsh, Roger von Moos, Vania Hungria, Roger Dansey

Support Care Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R Furman, Jeff P Sharman, Steven E Coutre, Bruce D Cheson, John M Pagel, Roger D Dansey

N Engl J Med· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Ajay K Gopal, Brad S Kahl, Sven de Vos, Nina D Wagner-Johnston, Stephen J Schuster, Roger D Dansey

N Engl J Med· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Matthew R Smith, Fred Saad, Stephane Oudard, Neal Shore, Karim Fizazi, Roger Dansey

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Authors' response to letter to the editor.
Alison Stopeck, David Henry, Roger Dansey, Yi Qian, Ze Cong

J Med Econ· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Charles S Cleeland, Jean-Jacques Body, Alison Stopeck, Roger von Moos, Lesley Fallowfield, Roger Dansey

Cancer· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Alison Stopeck, Michael Rader, David Henry, Mark Danese, Marc Halperin, Roger Dansey

J Med Econ· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Miguel Martin, Richard Bell, Hugues Bourgeois, Adam Brufsky, Ingo Diel, Roger Dansey

Clin Cancer Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
Carsten Goessl, Leonid Katz, William C Dougall, Paul J Kostenuik, Holly Brenza Zoog, Roger Dansey

Ann N Y Acad Sci· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
David L Lacey, William J Boyle, W Scott Simonet, Paul J Kostenuik, William C Dougall, Roger Dansey

Nat Rev Drug Discov· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
Matthew R Smith, Fred Saad, Robert Coleman, Neal Shore, Karim Fizazi, Roger Dansey

Lancet· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form.
Susan D Mathias, Ross D Crosby, Yi Qian, Qi Jiang, Roger Dansey

J Support Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
David H Henry, Luis Costa, Francois Goldwasser, Vera Hirsh, Vania Hungria, Roger Dansey

J Clin Oncol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Karim Fizazi, Michael Carducci, Matthew Smith, Ronaldo Damião, Janet Brown, Roger Dansey

Lancet· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Alison T Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G Steger, Katia Tonkin, Roger Dansey

J Clin Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
David Thomas, Robert Henshaw, Keith Skubitz, Sant Chawla, Arthur Staddon, Roger Dansey

Lancet Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
Jorge Sierra, Jeffrey Szer, Jeannine Kassis, Richard Herrmann, Mario Lazzarino, Roger Dansey

BMC Cancer· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease.
Edward Peres, Polly Kintzel, Roger Dansey, Roy Baynes, Muneer Abidi

Blood Coagul Fibrinolysis· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced intensity transplantation for metastatic renal cell cancer with 2-year follow-up.
Edward Peres, Muneer H Abidi, Stephanie Mellon-Reppen, Jared Klein, Tom Braun, Roger Dansey

J Immunother· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful bone marrow transplantation for life threatening xanthogranuloma disseminatum in neurofibromatosis type-1.
Süreyya Savaşan, Laurie Smith, Carolyn Scheer, Roger Dansey, Esteban Abella

Pediatr Transplant· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity.
Rami B Ibrahim, Edward Peres, Roger Dansey, Muneer H Abidi, Esteban M Abella

Ann Pharmacother· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Roy B Jones, Keith E Stockerl-Goldstein, Jared Klein, James Murphy, Karl G Blume, Roger Dansey

Biol Blood Marrow Transplant· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
Richard A Nash, Roger Dansey, Jan Storek, George E Georges, James D Bowen

Biol Blood Marrow Transplant· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis